Warnet A
Service Médecine B, Hôpital Lariboisière, Paris, France.
Metabolism. 1992 Sep;41(9 Suppl 2):59-61. doi: 10.1016/0026-0495(92)90032-6.
Octreotide may act on non-growth hormone-, non-thyroid-stimulating hormone, and non-prolactin-secreting adenomas. Its efficacy was reported in some corticotropin-secreting adenomas from Nelson's syndrome and from Cushing's disease. In gonadotropin-secreting adenomas, octreotide was shown to be effective in two of eight cases. In nonfunctioning adenomas, visual improvement was observed with octreotide in 14 of 23 cases in a French multicenter study. Among the 33 patients whose tumor volume was checked, shrinkage occurred in seven, but an increase in tumor volume was observed in another seven patients. Mechanism(s) and prediction of efficacy of octreotide remain to be documented.
奥曲肽可能作用于非生长激素、非促甲状腺激素和非泌乳素分泌性腺瘤。在一些来自尼尔森综合征和库欣病的促肾上腺皮质激素分泌性腺瘤中报道了其疗效。在促性腺激素分泌性腺瘤中，8例中有2例显示奥曲肽有效。在一项法国多中心研究中，23例无功能腺瘤患者中有14例使用奥曲肽后视力改善。在33例检查了肿瘤体积的患者中，7例肿瘤缩小，但另有7例患者肿瘤体积增大。奥曲肽的作用机制和疗效预测仍有待证实。
